

Preclinical study of DA-4505 for the treatment of cancer immunotherapy



| ONCOLOGY | Non-Clinical |
|--------------------------|---|
| Product Type | NCE |
| Indication | Advanced Solid Tumors (NSCLC, Colorectal Cancer MSS, Urothelial Carcinoma, HNSCC) |
| Target | Aryl hydrocarbon Receptor (AhR) |
| MoA(Mechanism of Action) | It is an antagonist to AhR reported to exhibit an immunosuppressive effect by inducing excessive activity by binding to kynurenine, a tryptophan metabolite produced excessively in the tumor microenvironment. |
| Competitiveness | <ul style="list-style-type: none"> • No drugs approved by the FDA to date. • DA-4505 shows superior cellular efficacy, PK profile, and broad therapeutic index (TI) than drugs of competitors currently being studied in the clinical phase. • AhR could be an attractive alternative target to overcome the limitation of IDO1 inhibitors because it directly inhibits kynurenine produced through several biological pathways. |
| Development Stage | Non-Clinical |
| Route of Administration | Orally(Q.D.) available small molecule |